The efficacy of fibrinogen concentrate compared with cryoprecipitate in major obstetric haemorrhage - an observational study.

Hdl Handle:
http://hdl.handle.net/10147/269761
Title:
The efficacy of fibrinogen concentrate compared with cryoprecipitate in major obstetric haemorrhage - an observational study.
Authors:
Ahmed, S; Harrity, C; Johnson, S; Varadkar, S; McMorrow, S; Fanning, R; Flynn, C M; O' Riordan, J M; Byrne, B M
Affiliation:
Department of Obstetrics and Gynaecology, Coombe Women and Infants University Hospital, Dublin, Ireland.
Citation:
The efficacy of fibrinogen concentrate compared with cryoprecipitate in major obstetric haemorrhage--an observational study. 2012, 22 (5):344-9 Transfus Med
Journal:
Transfusion medicine (Oxford, England)
Issue Date:
Oct-2012
URI:
http://hdl.handle.net/10147/269761
DOI:
10.1111/j.1365-3148.2012.01178.x
PubMed ID:
22994449
Abstract:
Fibrinogen replacement is critical in major obstetric haemorrhage (MOH). Purified, pasteurised fibrinogen concentrate appears to have benefit over cryoprecipitate in ease of administration and safety but is unlicensed in pregnancy. In July 2009, the Irish Blood Transfusion Service replaced cryoprecipitate with fibrinogen.
Item Type:
Article
Language:
en
MeSH:
Adult; Blood Loss, Surgical; Coagulants; Delivery, Obstetric; Factor VIII; Female; Fibrinogen; Hemorrhage; Humans; Ireland; Pregnancy; Prospective Studies
ISSN:
1365-3148

Full metadata record

DC FieldValue Language
dc.contributor.authorAhmed, Sen_GB
dc.contributor.authorHarrity, Cen_GB
dc.contributor.authorJohnson, Sen_GB
dc.contributor.authorVaradkar, Sen_GB
dc.contributor.authorMcMorrow, Sen_GB
dc.contributor.authorFanning, Ren_GB
dc.contributor.authorFlynn, C Men_GB
dc.contributor.authorO' Riordan, J Men_GB
dc.contributor.authorByrne, B Men_GB
dc.date.accessioned2013-02-19T13:03:48Z-
dc.date.available2013-02-19T13:03:48Z-
dc.date.issued2012-10-
dc.identifier.citationThe efficacy of fibrinogen concentrate compared with cryoprecipitate in major obstetric haemorrhage--an observational study. 2012, 22 (5):344-9 Transfus Meden_GB
dc.identifier.issn1365-3148-
dc.identifier.pmid22994449-
dc.identifier.doi10.1111/j.1365-3148.2012.01178.x-
dc.identifier.urihttp://hdl.handle.net/10147/269761-
dc.description.abstractFibrinogen replacement is critical in major obstetric haemorrhage (MOH). Purified, pasteurised fibrinogen concentrate appears to have benefit over cryoprecipitate in ease of administration and safety but is unlicensed in pregnancy. In July 2009, the Irish Blood Transfusion Service replaced cryoprecipitate with fibrinogen.en_GB
dc.language.isoenen
dc.rightsArchived with thanks to Transfusion medicine (Oxford, England)en_GB
dc.subject.meshAdult-
dc.subject.meshBlood Loss, Surgical-
dc.subject.meshCoagulants-
dc.subject.meshDelivery, Obstetric-
dc.subject.meshFactor VIII-
dc.subject.meshFemale-
dc.subject.meshFibrinogen-
dc.subject.meshHemorrhage-
dc.subject.meshHumans-
dc.subject.meshIreland-
dc.subject.meshPregnancy-
dc.subject.meshProspective Studies-
dc.titleThe efficacy of fibrinogen concentrate compared with cryoprecipitate in major obstetric haemorrhage - an observational study.en_GB
dc.typeArticleen
dc.contributor.departmentDepartment of Obstetrics and Gynaecology, Coombe Women and Infants University Hospital, Dublin, Ireland.en_GB
dc.identifier.journalTransfusion medicine (Oxford, England)en_GB
dc.description.provinceLeinsteren

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.